Topics

Sesen Bio, Inc. Company Profile

05:48 EDT 20th September 2019 | BioPortfolio

Sesen Bio, Inc. is a late-stage clinical company advancing next-generation antibody-drug conjugate therapies for the treatment of cancer based on the company’s Targeted Protein Therapeutics platform. The company’s lead program, Vicinium™, also known as VB4-845, is currently in a Phase 3 registration trial, the VISTA Trial, for the treatment of high-grade non-muscle invasive bladder cancer. Vicinium incorporates a tumor-targeting antibody fragment and a protein cytotoxic payload into a single protein molecule designed to selectively and effectively kill cancer cells while sparing healthy cells. For more information, please visit the company’s website at www.sesenbio.com.


News Articles [35 Associated News Articles listed on BioPortfolio]

Sesen Bio’s Richard Fitzgerald to Depart, Monica Forbes Is Named CFO

Richard Fitzgerald, chief financial officer of Sesen Bio (NASDAQ: SESN) for the past 19 months, will leave the company on Aug. 30, the company announced Monday. Cambridge, MA-based Sesen gave no reaso...

FDA accepts Sesen Bio's plan to ensure flagship drug vicinium’s manufacturing quality; shares jump

Sesen’s Canada facility produced vicinium for its Phase 2 and 3 clinical trials, but FUJIFILM Diosynth Biotechnologies USA will make the drug for commercial use

Sesen Bio nets $28.2mm through public offering

Sesen Bio Inc. (oncology) netted $28.2mm through a public offering of 20.4mm common shares at $1.47. Investors also received one-year warrants to purchase 20.4mm more shares at the purchase price. Pro...

5 Top Weekly NASDAQ Biotech and Pharma Stocks: Sesen Bio Up 40 Percent

Which NASDAQ biotech and pharma stocks were up last week? We examine the top five gainers and what may have moved their share prices. The post 5 Top Weekly NASDAQ Biotech and Pharma Stocks: Sesen Bio ...

Sesen Bio Looks Better Than Ever - An Update

Sesen Bio to Present at the Canaccord Genuity 39th Annual Growth Conference

Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced it will be featured as a presenting ...

Sesen Bio reports data update from phase 3 trial for high-risk non-muscle invasive bladder cancer

The updated preliminary Phase 3 clinical data will serve as the basis for the anticipated initiation of the Company’s BLA submission in 4Q 2019 “After two very positive The post Sesen Bio reports...

Sesen Bio to Present at the H.C. Wainwright 21st Annual Global Investment Conference

Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced it will be featured as a presenting ...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [1 Associated Companies listed on BioPortfolio]

Sesen Bio, Inc.

Sesen Bio, Inc. is a late-stage clinical company advancing next-generation antibody-drug conjugate therapies for the treatment of cancer based on the company’s Targeted Prote...

More Information about "Sesen Bio, Inc." on BioPortfolio

We have published hundreds of Sesen Bio, Inc. news stories on BioPortfolio along with dozens of Sesen Bio, Inc. Clinical Trials and PubMed Articles about Sesen Bio, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Sesen Bio, Inc. Companies in our database. You can also find out about relevant Sesen Bio, Inc. Drugs and Medications on this site too.

Quick Search

Corporate Database Quicklinks



Searches Linking to this Company Record